Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001635088-26-000017

President & Immunovant CEO sold 200,000 shares at $26.49 ($5,298,000)

  • President & Immunovant CEO acquired 200,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Venker Eric · President & Immunovant CEO

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-13 Exercise or conversion : show line 1 in the form 10b5-1 +200,000 $3.85 $770,000 1,854,597 D
2026-02-13 Sale : show line 2 in the form 10b5-1 −200,000 $26.49 $5,298,000 1,654,597 D
Open-market sales · 200,000 sh · avg $26.49 · $5,298,000

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-02-13 Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) −200,000 5,044,834 D
Loading xslF345X05/wk-form4_1771455431.xml…